Perrigo Company

Perrigo Company EBIT Margin

The EBIT Margin (Operating Margin) of Perrigo Company (PRGO) as of Nov 3, 2026 is 8.07 %. In the previous year, EBIT Margin (Operating Margin) was 2.58 % — a change of 212.68% (higher).

EBIT Margin

8.07 %

YoY

212.68%

Last updated:

EBIT Margin (Operating Margin) of Perrigo Company is 2025 8.07 % . EBIT Margin (Operating Margin) of Perrigo Company was 2024 2.58 % . It decreases by 212.68% higher compared to the previous year.

Perrigo Company's operating (EBIT) margin stands at 8.1%, down from 9.9% several years earlier.

The Perrigo Company EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2018
7.70 USD
Jan 1, 2019
4.51 USD
Jan 1, 2020
3.27 USD
Jan 1, 2021
9.92 USD
Jan 1, 2022
1.77 USD
Jan 1, 2023
3.26 USD
Jan 1, 2024
2.58 USD
Jan 1, 2025
8.07 USD
The Perrigo Company EBIT Margin history
YEAREBIT MarginYoY
8.07 %+212.68%
2.58 %-20.88%
3.26 %+84.09%
1.77 %-82.13%
9.92 %+203.44%
3.27 %-27.61%
4.51 %-41.40%
7.70 %-36.30%
12.09 %-113.79%
-87.71 %-640.15%
16.24 %+16.30%
13.96 %+14,032.60%
0.10 %-48.50%
0.19 %+6.95%
0.18 %+0.82%
0.18 %+20.19%
0.15 %+20.14%
0.12 %+13.70%
0.11 %+59.18%
0.07 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Perrigo Company Stock analysis

What does Perrigo Company do? The Perrigo Company PLC is a globally operating company in the pharmaceutical and healthcare products sector. The company was founded in 1887 as The Donerail Corporation and is headquartered in Dublin, Ireland. Perrigo's business model focuses on healthcare products and offers a wide range of products, ranging from over-the-counter medications to dietary supplements and personal care products. The company is divided into three business segments: Consumer Healthcare Americas, serving the markets in North, Central, and South America; Consumer Healthcare International, serving the markets in Europe, Australasia, Asia, and Israel; and Pharmaceutical, which includes pharmaceutical manufacturing and development. The Consumer Healthcare Americas segment focuses on developing products that aid in the treatment and prevention of various health issues. Some of the well-known products include the dietary supplement brand Emergen-C, the allergy and sinus product brand GoodSense, and the pain relief brand TopCare. Consumer Healthcare International offers similar products to the Consumer Healthcare Americas segment, but with a focus on the international market. The product range includes pain relief, cold and flu products, skincare products, vitamins and minerals, oral care products, and household products. The Pharmaceutical segment specializes in the manufacturing and development of generic drugs, biosimilars, and over-the-counter medications. The company has extensive experience in generics manufacturing and has recently expanded its product portfolio to include biologics and pharmaceutical development. Perrigo's pharmaceutical products are widely recognized and sold in many countries. Some of the well-known products include the blockbuster injectable methotrexate Heumann, a highly effective immunosuppressant used in the treatment of autoimmune diseases. Perrigo is a leading provider of quality products and continuously develops new products to meet the needs of its customers. The company places a high value on research and development and works closely with professionals in the medical field. Perrigo has established an extensive global distribution network to ensure its products are available worldwide. In recent years, the company has strengthened its market presence through mergers and acquisitions. In 2015, Perrigo acquired Irish pharmaceutical company Elan Corporation, which specializes in the development of drugs for neurodegenerative diseases. This acquisition expanded Perrigo's product portfolio in biologics development. Since 2019, Ranir, a global leader in oral care products, has also been integrated into the company. In the recent past, Perrigo has set a target date by which it aims to resolve tax issues related to a series of disputed transactions with the IRS. The target is the end of June 2021, by which the company aims to achieve a satisfactory outcome and move forward. Overall, Perrigo has a successful history as a leading provider of pharmaceutical and healthcare products. The company is able to meet the needs of its customers worldwide by offering a wide range of products, from over-the-counter medications to dietary supplements and personal care products. With a strong focus on research and development, Perrigo has strengthened its market presence through mergers and acquisitions in recent years, promising a bright future for the company. Perrigo Company is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Perrigo Company stock

EBIT Margin (Operating Margin) of Perrigo Company is 8.07 % in 2025.

EBIT Margin (Operating Margin) of Perrigo Company changed from 2.58 % to 8.07 %, representing a 212.68% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Perrigo Company since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Perrigo Company with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Perrigo Company

All Key Metrics — Perrigo Company